Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatmen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/2/94 |
| _version_ | 1797406896123019264 |
|---|---|
| author | Joel Mintz Anastasia Vedenko Omar Rosete Khushi Shah Gabriella Goldstein Joshua M. Hare Ranjith Ramasamy Himanshu Arora |
| author_facet | Joel Mintz Anastasia Vedenko Omar Rosete Khushi Shah Gabriella Goldstein Joshua M. Hare Ranjith Ramasamy Himanshu Arora |
| author_sort | Joel Mintz |
| collection | DOAJ |
| description | Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumorigenic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the level of production, the oxidative/reductive (redox) environment in which this radical is generated, the presence or absence of NO transduction elements, and the tumor microenvironment. Generally, there are four major categories of NO-based anticancer therapies: NO donors, phosphodiesterase inhibitors (PDE-i), soluble guanylyl cyclase (sGC) activators, and immunomodulators. Of these, NO donors are well studied, well characterized, and also the most promising. In this study, we review the current knowledge in this area, with an emphasis placed on the role of NO as an anticancer therapy and dysregulated molecular interactions during the evolution of cancer, highlighting the strategies that may aid in the targeting of cancer. |
| first_indexed | 2024-03-09T03:33:20Z |
| format | Article |
| id | doaj.art-4132f2d054b14042b623a09bf08eea95 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:33:20Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-4132f2d054b14042b623a09bf08eea952023-12-03T14:52:07ZengMDPI AGVaccines2076-393X2021-01-01929410.3390/vaccines9020094Current Advances of Nitric Oxide in Cancer and Anticancer TherapeuticsJoel Mintz0Anastasia Vedenko1Omar Rosete2Khushi Shah3Gabriella Goldstein4Joshua M. Hare5Ranjith Ramasamy6Himanshu Arora7Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USAJohn P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USADepartment of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USACollege of Arts and Sciences, University of Miami, Miami, FL 33146, USACollege of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USAJohn P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USADepartment of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USAJohn P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USANitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumorigenic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the level of production, the oxidative/reductive (redox) environment in which this radical is generated, the presence or absence of NO transduction elements, and the tumor microenvironment. Generally, there are four major categories of NO-based anticancer therapies: NO donors, phosphodiesterase inhibitors (PDE-i), soluble guanylyl cyclase (sGC) activators, and immunomodulators. Of these, NO donors are well studied, well characterized, and also the most promising. In this study, we review the current knowledge in this area, with an emphasis placed on the role of NO as an anticancer therapy and dysregulated molecular interactions during the evolution of cancer, highlighting the strategies that may aid in the targeting of cancer.https://www.mdpi.com/2076-393X/9/2/94immunotherapynitric oxideprostate cancercastrationcheckpoint inhibitors |
| spellingShingle | Joel Mintz Anastasia Vedenko Omar Rosete Khushi Shah Gabriella Goldstein Joshua M. Hare Ranjith Ramasamy Himanshu Arora Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Vaccines immunotherapy nitric oxide prostate cancer castration checkpoint inhibitors |
| title | Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics |
| title_full | Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics |
| title_fullStr | Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics |
| title_full_unstemmed | Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics |
| title_short | Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics |
| title_sort | current advances of nitric oxide in cancer and anticancer therapeutics |
| topic | immunotherapy nitric oxide prostate cancer castration checkpoint inhibitors |
| url | https://www.mdpi.com/2076-393X/9/2/94 |
| work_keys_str_mv | AT joelmintz currentadvancesofnitricoxideincancerandanticancertherapeutics AT anastasiavedenko currentadvancesofnitricoxideincancerandanticancertherapeutics AT omarrosete currentadvancesofnitricoxideincancerandanticancertherapeutics AT khushishah currentadvancesofnitricoxideincancerandanticancertherapeutics AT gabriellagoldstein currentadvancesofnitricoxideincancerandanticancertherapeutics AT joshuamhare currentadvancesofnitricoxideincancerandanticancertherapeutics AT ranjithramasamy currentadvancesofnitricoxideincancerandanticancertherapeutics AT himanshuarora currentadvancesofnitricoxideincancerandanticancertherapeutics |